Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial
Annals of Oncology(2022)
Abstract
RNAseq is a promising approach to monitor changes in the tumor microenvironment since it allows for multiple genes evaluation. We analyzed the differential immune expression pattern between pre- and post-treatment tissue samples of stage III NSCLC patients treated with neoadjuvant chemoimmunotherapy from the NADIM trial.
MoreTranslated text
Key words
neoadjuvant chemoimmunotherapy treatment,immune gene signatures,nsclc patients,nadim trial
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined